Skip to main content
Top
Published in: Lung 2/2011

01-04-2011

Assessment of Small-Airways Disease Using Alveolar Nitric Oxide and Impulse Oscillometry in Asthma and COPD

Authors: Peter A. Williamson, Karine Clearie, Daniel Menzies, Sriram Vaidyanathan, Brian J. Lipworth

Published in: Lung | Issue 2/2011

Login to get access

Abstract

The contribution of the alveolar compartment to exhaled nitric oxide (alveolar nitric oxide or CANO) can be calculated as a surrogate of distal inflammation. This value should be corrected for nitric oxide produced in the conducting airways which “back-diffuses” into the alveolar compartment (Corrected CANO). Impulse oscillometry (IOS) (Nava et al., Am J Respir Crit Care Med 168:1432–1437, 2003) is used to derive values for peripheral airways resistance. Twenty-four healthy volunteers, 21 severe asthmatics, 15 mild-to-moderate asthmatics, and 24 COPD patients were assessed with spirometry, impulse oscillometry, and fractionated exhaled nitric oxide. Compared to healthy volunteers, FENO was higher in mild-to-moderate and severe asthmatics: geometric mean fold ratios of 1.91 (P = 0.02) and 2.74 (P < 0.001), respectively. However, there was no difference for mild-to-moderate versus severe asthma. Ratios for CANO were not different for severe asthma versus COPD, but both were elevated compared to that of healthy volunteers [2.64 (P < 0.001) and 3.07 (P < 0.001), respectively] and mild-to-moderate asthma [1.95 (P = 0.04) and 2.28 (P < 0.01)]. However, after correction for axial diffusion, Corrected CANO was increased in COPD compared to severe asthma (geometric mean fold ratio 1.28, P = 0.04), mild-to-moderate asthma (1.34, P < 0.01), and healthy volunteers (1.28, P = 0.02), and there was no difference between other groups. R5 and RF were reduced in healthy volunteers versus mild-to-moderate asthma (P = 0.011 and P < 0.001 respectively), severe asthma (P = 0.002 and P < 0.001), and COPD (P < 0.001 and P < 0.001). Peripheral resistance (R5–R20) was not different for healthy versus mild-to-moderate asthma but was higher in severe asthma (P < 0.001) and COPD (P < 0.001). Correlations were observed between R5–R20 versus FEF25–75 (r = 0.71, P < 0.01), CANO (r = 0.44, P < 0.01), and Corrected CANO (r = 0.24, P < 0.01). CANO and IOS provide additional information to traditional measures of spirometry and tidal nitric oxide. Previous data reporting elevated alveolar nitric oxide in severe asthma may reflect back-diffusion of nitric oxide from the conducting airways into the alveolar compartment. Corrected CANO and IOS may prove to be useful noninvasive measurements of small-airways disease.
Literature
1.
go back to reference Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, Silverman EK, Tal-Singer R (2008) Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 31:869–873PubMedCrossRef Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, Silverman EK, Tal-Singer R (2008) Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 31:869–873PubMedCrossRef
2.
go back to reference Taylor DR (2009) Risk assessment in asthma and COPD: a potential role for biomarkers? Thorax 64:261–264PubMedCrossRef Taylor DR (2009) Risk assessment in asthma and COPD: a potential role for biomarkers? Thorax 64:261–264PubMedCrossRef
3.
go back to reference Brightling CE, Green RH, Pavord ID (2005) Biomarkers predicting response to corticosteroid therapy in asthma. Treat Respir Med 4:309–316PubMedCrossRef Brightling CE, Green RH, Pavord ID (2005) Biomarkers predicting response to corticosteroid therapy in asthma. Treat Respir Med 4:309–316PubMedCrossRef
4.
go back to reference Sont JK, Willems LNA, Bel EH, van Krieken HJM, Vandenbroucke JP, Sterk PJ (1999) Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 159:1043–1051PubMed Sont JK, Willems LNA, Bel EH, van Krieken HJM, Vandenbroucke JP, Sterk PJ (1999) Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 159:1043–1051PubMed
5.
go back to reference Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID (2002) Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360:15–21CrossRef Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID (2002) Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360:15–21CrossRef
6.
go back to reference American Thoracic Society (2000) Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 162:2341–2351 American Thoracic Society (2000) Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 162:2341–2351
7.
go back to reference American Thoracic Society; European Respiratory Society (2005) ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 171:912–930CrossRef American Thoracic Society; European Respiratory Society (2005) ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 171:912–930CrossRef
8.
go back to reference American Thoracic Society Workshop (2006) ATS Workshop Proceedings: Exhaled nitric oxide and nitric oxide oxidative metabolism in exhaled breath condensate: executive summary. Am J Respir Crit Care Med 173:811–813CrossRef American Thoracic Society Workshop (2006) ATS Workshop Proceedings: Exhaled nitric oxide and nitric oxide oxidative metabolism in exhaled breath condensate: executive summary. Am J Respir Crit Care Med 173:811–813CrossRef
9.
go back to reference Tsoukias NM, George SC (1998) A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 85:653–666PubMed Tsoukias NM, George SC (1998) A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 85:653–666PubMed
10.
go back to reference Tsoukias NM, Shin HW, Wilson AF, George SC (2001) A single-breath technique with variable flow rate to characterize nitric oxide exchange dynamics in the lungs. J Appl Physiol 91:477–487PubMed Tsoukias NM, Shin HW, Wilson AF, George SC (2001) A single-breath technique with variable flow rate to characterize nitric oxide exchange dynamics in the lungs. J Appl Physiol 91:477–487PubMed
11.
go back to reference Berry M, Hargadon B, Morgan A, Shelley M, Richter J, Shaw D, Green RH, Brightling C, Wardlaw AJ, Pavord ID (2005) Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J 25:986–991PubMedCrossRef Berry M, Hargadon B, Morgan A, Shelley M, Richter J, Shaw D, Green RH, Brightling C, Wardlaw AJ, Pavord ID (2005) Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J 25:986–991PubMedCrossRef
12.
go back to reference Cohen J, Douma WR, ten Hacken NH, Vonk JM, Oudkerk M, Postma DS (2008) Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J 31(6):1213–1220PubMedCrossRef Cohen J, Douma WR, ten Hacken NH, Vonk JM, Oudkerk M, Postma DS (2008) Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J 31(6):1213–1220PubMedCrossRef
13.
go back to reference Williamson PA, Menzies D, Nair A, Tutuncu A, Lipworth BJ (2009) A proof-of-concept study to evaluate the antiinflammatory effects of a novel soluble cyclodextrin formulation of nebulized budesonide in patients with mild to moderate asthma. Ann Allergy Asthma Immunol 102:161–167PubMedCrossRef Williamson PA, Menzies D, Nair A, Tutuncu A, Lipworth BJ (2009) A proof-of-concept study to evaluate the antiinflammatory effects of a novel soluble cyclodextrin formulation of nebulized budesonide in patients with mild to moderate asthma. Ann Allergy Asthma Immunol 102:161–167PubMedCrossRef
14.
go back to reference Condorelli P, Shin HW, George SC (2004) Characterizing airway and alveolar nitric oxide exchange during tidal breathing using a three-compartment model. J Appl Physiol 96:1832–1842PubMedCrossRef Condorelli P, Shin HW, George SC (2004) Characterizing airway and alveolar nitric oxide exchange during tidal breathing using a three-compartment model. J Appl Physiol 96:1832–1842PubMedCrossRef
15.
go back to reference Kerckx Y, Michils A, Van Muylem A (2008) Airway contribution to alveolar nitric oxide in healthy subjects and stable asthma patients. J Appl Physiol 104:918–924PubMedCrossRef Kerckx Y, Michils A, Van Muylem A (2008) Airway contribution to alveolar nitric oxide in healthy subjects and stable asthma patients. J Appl Physiol 104:918–924PubMedCrossRef
16.
go back to reference Condorelli P, Shin HW, Aledia AS, Silkoff PE, George SC (2007) A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model. J Appl Physiol 102:417–425PubMedCrossRef Condorelli P, Shin HW, Aledia AS, Silkoff PE, George SC (2007) A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model. J Appl Physiol 102:417–425PubMedCrossRef
17.
go back to reference Dubois AB, Brody AW, Lewis DH, Burgess BF Jr (1956) Oscillation mechanics of lungs and chest in man. J Appl Physiol 8:587–594PubMed Dubois AB, Brody AW, Lewis DH, Burgess BF Jr (1956) Oscillation mechanics of lungs and chest in man. J Appl Physiol 8:587–594PubMed
18.
go back to reference Oostveen E, MacLeod D, Lorino H, Farre R, Hantos Z, Desager K, Marchal F (2003) The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J 22:1026–1041PubMedCrossRef Oostveen E, MacLeod D, Lorino H, Farre R, Hantos Z, Desager K, Marchal F (2003) The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J 22:1026–1041PubMedCrossRef
19.
go back to reference Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J (2005) Standardisation of spirometry. Eur Respir J 26:319–338PubMedCrossRef Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J (2005) Standardisation of spirometry. Eur Respir J 26:319–338PubMedCrossRef
20.
go back to reference Borrill ZL, Houghton CM, Woodcock AA, Vestbo J, Singh D (2005) Measuring bronchodilation in COPD clinical trials. Br J Clin Pharmacol 59:379–384PubMedCrossRef Borrill ZL, Houghton CM, Woodcock AA, Vestbo J, Singh D (2005) Measuring bronchodilation in COPD clinical trials. Br J Clin Pharmacol 59:379–384PubMedCrossRef
21.
go back to reference Fardon TC, Burns P, Barnes ML, Lipworth BJ (2006) A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness. Ann Allergy Asthma Immunol 96:422–430PubMedCrossRef Fardon TC, Burns P, Barnes ML, Lipworth BJ (2006) A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness. Ann Allergy Asthma Immunol 96:422–430PubMedCrossRef
22.
go back to reference Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, Pavord ID (2007) The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 176:231–237PubMedCrossRef Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, Pavord ID (2007) The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 176:231–237PubMedCrossRef
23.
go back to reference Gelb AF, Taylor CF, Nussbaum E, Gutierrez C, Schein A, Shinar CM, Schein MJ, Epstein JD, Zamel N (2004) Alveolar and airway sites of nitric oxide inflammation in treated asthma. Am J Respir Crit Care Med 170:737–741PubMedCrossRef Gelb AF, Taylor CF, Nussbaum E, Gutierrez C, Schein A, Shinar CM, Schein MJ, Epstein JD, Zamel N (2004) Alveolar and airway sites of nitric oxide inflammation in treated asthma. Am J Respir Crit Care Med 170:737–741PubMedCrossRef
24.
go back to reference van Veen IH, Sterk PJ, Schot R, Gauw SA, Rabe KF, Bel EH (2006) Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur Respir J 27:951–956PubMed van Veen IH, Sterk PJ, Schot R, Gauw SA, Rabe KF, Bel EH (2006) Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur Respir J 27:951–956PubMed
25.
go back to reference Berry MA, Shaw D, Morgan A, Hargadon B, McKenna S, Shelley M, Green RH, Brightling CE, Wardlaw AJ, Pavord ID (2004) Association between alveolar nitric oxide concentration and broncheoalveolar lavage but not bronchial wash eosinophil count in patients with asthma. Thorax 59:ii50 Berry MA, Shaw D, Morgan A, Hargadon B, McKenna S, Shelley M, Green RH, Brightling CE, Wardlaw AJ, Pavord ID (2004) Association between alveolar nitric oxide concentration and broncheoalveolar lavage but not bronchial wash eosinophil count in patients with asthma. Thorax 59:ii50
26.
go back to reference Brindicci C, Ito K, Barnes PJ, Kharitonov SA (2007) Differential flow analysis of exhaled nitric oxide in patients with asthma of differing severity. Chest 131:1353–1362PubMedCrossRef Brindicci C, Ito K, Barnes PJ, Kharitonov SA (2007) Differential flow analysis of exhaled nitric oxide in patients with asthma of differing severity. Chest 131:1353–1362PubMedCrossRef
27.
go back to reference Saari SM, Vidgren MT, Koskinen MO, Turjanmaa VM, Waldrep JC, Nieminen MM (1998) Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest 113:1573–1579PubMedCrossRef Saari SM, Vidgren MT, Koskinen MO, Turjanmaa VM, Waldrep JC, Nieminen MM (1998) Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest 113:1573–1579PubMedCrossRef
28.
go back to reference Brindicci C, Ito K, Resta O, Pride NB, Barnes PJ, Kharitonov SA (2005) Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J 26:52–59PubMedCrossRef Brindicci C, Ito K, Resta O, Pride NB, Barnes PJ, Kharitonov SA (2005) Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J 26:52–59PubMedCrossRef
29.
go back to reference Roy K, Borrill ZL, Starkey C, Hazel AL, Morris J, Vestbo J, Singh D (2007) Use of different exhaled nitric oxide multiple flow rate models in COPD. Eur Respir J 29:651–659PubMedCrossRef Roy K, Borrill ZL, Starkey C, Hazel AL, Morris J, Vestbo J, Singh D (2007) Use of different exhaled nitric oxide multiple flow rate models in COPD. Eur Respir J 29:651–659PubMedCrossRef
30.
go back to reference Borrill ZL, Houghton CM, Tal-Singer R, Vessey SR, Faiferman I, Langley SJ, Singh D (2008) The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. Br J Clin Pharmacol 65:244–252PubMedCrossRef Borrill ZL, Houghton CM, Tal-Singer R, Vessey SR, Faiferman I, Langley SJ, Singh D (2008) The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. Br J Clin Pharmacol 65:244–252PubMedCrossRef
31.
go back to reference Houghton CM, Woodcock AA, Singh D (2004) A comparison of lung function methods for assessing dose-response effects of salbutamol. Br J Clin Pharmacol 58:134–141PubMedCrossRef Houghton CM, Woodcock AA, Singh D (2004) A comparison of lung function methods for assessing dose-response effects of salbutamol. Br J Clin Pharmacol 58:134–141PubMedCrossRef
32.
go back to reference Van Noord JA, Smeets J, Clement J, Van de Woestijne KP, Demedts M (1994) Assessment of reversibility of airflow obstruction. Am J Respir Crit Care Med 150:551–554PubMed Van Noord JA, Smeets J, Clement J, Van de Woestijne KP, Demedts M (1994) Assessment of reversibility of airflow obstruction. Am J Respir Crit Care Med 150:551–554PubMed
33.
go back to reference Burns GP, Gibson GJ (2002) A novel hypothesis to explain the bronchconstrictor effect of deep inspiration in asthma. Thorax 57:116–119PubMedCrossRef Burns GP, Gibson GJ (2002) A novel hypothesis to explain the bronchconstrictor effect of deep inspiration in asthma. Thorax 57:116–119PubMedCrossRef
34.
go back to reference Kolsum U, Borrill Z, Roy K, Starkey C, Vestbo J, Houghton C, Singh D (2009) Impulse oscillometry in COPD: identification of measurements related to airway obstruction, airway conductance and lung volumes. Respir Med 103:136–143PubMedCrossRef Kolsum U, Borrill Z, Roy K, Starkey C, Vestbo J, Houghton C, Singh D (2009) Impulse oscillometry in COPD: identification of measurements related to airway obstruction, airway conductance and lung volumes. Respir Med 103:136–143PubMedCrossRef
Metadata
Title
Assessment of Small-Airways Disease Using Alveolar Nitric Oxide and Impulse Oscillometry in Asthma and COPD
Authors
Peter A. Williamson
Karine Clearie
Daniel Menzies
Sriram Vaidyanathan
Brian J. Lipworth
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Lung / Issue 2/2011
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-010-9275-y

Other articles of this Issue 2/2011

Lung 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.